Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1920 1
1922 1
1925 1
1951 1
1953 1
1954 1
1955 1
1958 1
1962 1
1965 1
1968 1
1970 1
1971 1
1972 2
1974 4
1975 4
1976 2
1977 1
1978 7
1979 8
1980 11
1981 2
1982 11
1983 4
1984 1
1985 4
1986 2
1987 1
1988 2
1990 8
1991 1
1992 1
1993 1
1994 1
1995 2
1997 2
1999 21
2000 13
2001 10
2002 15
2003 20
2004 31
2005 38
2006 29
2007 14
2008 6
2009 13
2010 9
2011 12
2012 10
2013 7
2014 14
2015 8
2016 13
2017 24
2018 35
2019 31
2020 30
2021 38
2022 22
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

519 results

Results by year

Filters applied: . Clear all
Page 1
MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity.
Cheng D, Zinker BA, Luo Y, Shipkova P, De Oliveira CH, Krishna G, Brown EA, Boehm SL, Tirucherai GS, Gu H, Ma Z, Chu CH, Onorato JM, Kopcho LM, Ammar R, Smith J, Devasthale P, Lawrence RM, Stryker SA, Dierks EA, Azzara AV, Carayannopoulos L, Charles ED, Lentz KA, Gordon DA. Cheng D, et al. Among authors: charles ed. Cell Metab. 2022 Nov 1;34(11):1732-1748.e5. doi: 10.1016/j.cmet.2022.10.007. Cell Metab. 2022. PMID: 36323235 Free article.
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).
Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Corte TJ, et al. Among authors: charles ed. BMJ Open Respir Res. 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026. BMJ Open Respir Res. 2021. PMID: 34969771 Free PMC article. Clinical Trial.
Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.
Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, Mumtaz M, Olsen PS, Heiser JC, Merhi W, Kleiman NS, Chetcuti SJ, Gleason TG, Lee JS, Cheng W, Makkar RR, Crestanello J, George B, George I, Kodali S, Yakubov SJ, Serruys PW, Lange R, Piazza N, Williams MR, Oh JK, Adams DH, Li S, Reardon MJ; SURTAVI Trial Investigators. Van Mieghem NM, et al. JAMA Cardiol. 2022 Oct 1;7(10):1000-1008. doi: 10.1001/jamacardio.2022.2695. JAMA Cardiol. 2022. PMID: 36001335 Free PMC article. Clinical Trial.
Poetry corner.
Charles EP. Charles EP. Hist Psychol. 2018 May;21(2):172-175. doi: 10.1037/hop0000091b. Hist Psychol. 2018. PMID: 29745696
The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.
Morales-Arráez D, Ventura-Cots M, Altamirano J, Abraldes JG, Cruz-Lemini M, Thursz MR, Atkinson SR, Sarin SK, Kim W, Chavez-Araujo R, Higuera-de la Tijera MF, Singal AK, Shah VH, Kamath PS, Duarte-Rojo A, Charles EA, Vargas V, Jager M, Rautou PE, Rincon D, Zamarripa F, Restrepo-Gutiérrez JC, Torre A, Lucey MR, Arab JP, Mathurin P, Louvet A, García-Tsao G, González JA, Verna EC, Brown RS Jr, Argemi J, Fernández-Carrillo C, Clemente A, Alvarado-Tapias E, Forrest E, Allison M, Bataller R. Morales-Arráez D, et al. Among authors: charles ea. Am J Gastroenterol. 2022 Feb 1;117(2):301-310. doi: 10.14309/ajg.0000000000001596. Am J Gastroenterol. 2022. PMID: 34962498 Free PMC article.
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, Harrison SA, Jacobson IM, Imajo K, Gunn N, Halegoua-DeMarzio D, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Loomba R. Abdelmalek MF, et al. Among authors: charles ed. Clin Gastroenterol Hepatol. 2024 Jan;22(1):113-123.e9. doi: 10.1016/j.cgh.2023.04.012. Epub 2023 Apr 23. Clin Gastroenterol Hepatol. 2024. PMID: 37088458 Free article. Clinical Trial.
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Sanyal A, Charles ED, Neuschwander-Tetri BA, Loomba R, Harrison SA, Abdelmalek MF, Lawitz EJ, Halegoua-DeMarzio D, Kundu S, Noviello S, Luo Y, Christian R. Sanyal A, et al. Among authors: charles ed. Lancet. 2019 Dec 22;392(10165):2705-2717. doi: 10.1016/S0140-6736(18)31785-9. Epub 2018 Dec 13. Lancet. 2019. PMID: 30554783 Clinical Trial.
How to build and sustain an academic cardiothoracic surgery program.
Yarboro LT, Mehaffey JH, Charles EJ, Kron IL. Yarboro LT, et al. Among authors: charles ej. J Thorac Cardiovasc Surg. 2022 Apr;163(4):1431-1434. doi: 10.1016/j.jtcvs.2021.03.129. Epub 2021 May 13. J Thorac Cardiovasc Surg. 2022. PMID: 34090693 Free article. No abstract available.
[Complications of autism].
de Pontual L, Heulin M, Charles E, Héron B, Zylberberg P. de Pontual L, et al. Among authors: charles e. Arch Pediatr. 2015 May;22(5 Suppl 1):179-80. doi: 10.1016/S0929-693X(15)30089-0. Arch Pediatr. 2015. PMID: 26112580 French. No abstract available.
519 results